SCHEMBL16612834

SCHEMBL16612834

COc1ccc(OC)c(C=CC2=CC(=O)[C@H]3C[C@@H]2C3(C)C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 5/20 0.48
CYP1B1 Q16678 5/20 0.48
CYP1A2 P05177 4/20 0.48
NFE2L2 Q16236 3/20 0.48
JUN P05412 1/20 0.45
NFKB1 P19838 1/20 0.45
TLR9 Q9NR96 2/20 0.44
CYP19A1 P11511 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.42
POLB P06746 1/20 0.41
NCOA1 Q15788 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
MAPT P10636 1/20 0.39
SIRT1 Q96EB6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16612832 1.00 CYP1A1 (0.48) CYP1A1CYP1B1CYP1A2NFE2L2JUN
SCHEMBL16612833 1.00 CYP1A1 (0.48) CYP1A1CYP1B1CYP1A2NFE2L2JUN
SCHEMBL30284444 0.87 TNFRSF1A (0.40) CYP1A2MEN1KMT2AMAPT
SCHEMBL16612696 0.87 TNFRSF1A (0.40) CYP1A2MEN1KMT2AMAPT
SCHEMBL16612829 0.87 TNFRSF1A (0.40) CYP1A2MEN1KMT2AMAPT
SCHEMBL30284575 0.85 CYP1A1 (0.47) CYP1A1CYP1B1CYP1A2MEN1KMT2A
SCHEMBL16612717 0.85 CYP1A1 (0.47) CYP1A1CYP1B1CYP1A2MEN1KMT2A
SCHEMBL16612609 0.85 CYP1A1 (0.47) CYP1A1CYP1B1CYP1A2MEN1KMT2A
SCHEMBL16612610 0.85 CYP1A1 (0.47) CYP1A1CYP1B1CYP1A2MEN1KMT2A
SCHEMBL38655897 0.84 CYP3A4 (0.44) CYP1A1CYP1B1CYP1A2NFE2L2CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240415787-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2024-12-19 US claimed
EP-4397304-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES Shin Poong Pharmaceutical Co., Ltd. (KR) 2024-07-10 EP claimed
CN-117897145-A Composition for treating or preventing obesity or obesity-related liver diseases comprising verbenone derivatives 韩国新丰制药株式会社 2024-04-16 CN claimed
WO-2023033517-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES 신풍제약주식회사 2023-03-09 WO claimed
US-10710951-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-07-14 US claimed
EP-2857007-B1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE UNIV KOREA RES & BUS FOUND (KR) 2018-03-28 EP claimed
US-20170166505-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-15 US claimed
US-9603842-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2017-03-28 US claimed
US-20150148362-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2015-05-28 US claimed
EP-2857007-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE Korea University Research and Business Foundation (KR) 2015-04-08 EP claimed
US-20240415787-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2024-12-19 US disclosed
EP-4397304-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES Shin Poong Pharmaceutical Co., Ltd. (KR) 2024-07-10 EP disclosed
CN-117897145-A Composition for treating or preventing obesity or obesity-related liver diseases comprising verbenone derivatives 韩国新丰制药株式会社 2024-04-16 CN disclosed
WO-2023033517-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES 신풍제약주식회사 2023-03-09 WO disclosed
US-10710951-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-07-14 US disclosed
EP-2857007-B1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE UNIV KOREA RES & BUS FOUND (KR) 2018-03-28 EP disclosed
US-20170166505-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-15 US disclosed
US-9603842-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2017-03-28 US disclosed
US-20150148362-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2015-05-28 US disclosed
EP-2857007-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE Korea University Research and Business Foundation (KR) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166505-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE CASP3, DCX, BAX CYP1A1 2645/4885CYP1B1 3211/4885CYP1A2 2981/4885
US-10710951-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease CASP3, DCX, BAX CYP1A1 2645/4885CYP1B1 3211/4885CYP1A2 2981/4885
US-20240415787-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES SMAD3, TGFB1, TGFB2 CYP1A1 1491/4885CYP1B1 2045/4885CYP1A2 1795/4885
US-20150148362-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE CASP3, DCX, BAX CYP1A1 2645/4885CYP1B1 3211/4885CYP1A2 2981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.